Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Adds to Cardiovascular Portfolio With Launch of First Generic of Brevibloc® Injection in Single-Dose Bags
- Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate - HERTFORDSHIRE, England and PITTSBURGH , Sept. 13, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Esmolol Hydrochloride in Sodium Chloride Injection,
View HTML
Toggle Summary Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018
Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , Sept. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") and Mylan
View HTML
Toggle Summary Mylan Statement: Novartis TOBI Podhaler® and TOBI® Solution Agreement
We are pleased to confirm that on Aug. 31, 2018, Mylan closed an agreement with Novartis to purchase the worldwide rights to commercialize their global cystic fibrosis products consisting of TOBI Podhaler® and TOBI® solution, which will further enhance Mylan’s respiratory portfolio in the U.S.,
View HTML
Toggle Summary Mylan Launches First Generic for Adcirca® Tablets
- Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability - - Mylan awarded 180 days of marketing exclusivity - HERTFORDSHIRE, England and PITTSBURGH , Aug. 13, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
View HTML
Toggle Summary Statement from Mylan's Board of Directors
HERTFORDSHIRE, England , Aug. 8, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.'s (NASDAQ: MYL) board of directors today released the following statement: Over the past decade, Mylan's Board of Directors and management team have turned Mylan into a leading global platform with a
View HTML
Toggle Summary Mylan Reports Second Quarter 2018 Results and Updates 2018 Guidance
HERTFORDSHIRE, England and PITTSBURGH , Aug. 8, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced its financial results for the quarter and six months ended June 30, 2018. Second Quarter 2018 Financial Highlights Total revenues of $2.81 billion , down 5% compared to the prior year
View HTML
Toggle Summary Mylan to Release Second Quarter 2018 Financial Results on August 8, 2018
HERTFORDSHIRE, England , and PITTSBURGH , July 31, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2018 financial results, on Wed., Aug. 8 , before the open of the U.S.
View HTML
Toggle Summary Mylan and Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion for Hulio™, Biosimilar Adalimumab
HERTFORDSHIRE , England and PITTSBURGH, and TOKYO , July 27, 2018 /PRNewswire/ --  Mylan N.V.  (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the
View HTML
Toggle Summary Mylan Again Defeats Allergan's Efforts to Deny Patients Access to More Affordable Medicine
U.S. Court of Appeals for the Federal Circuit rejects Allergan's attempt to use tribal sovereign immunity to avoid Restasis® patent challenge Mylan's IPR challenges to Restasis® patents can proceed Federal District Court previously held patents invalid HERTFORDSHIRE, England and PITTSBURGH, July
View HTML
Toggle Summary Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon® Patch
- The launch of Rivastigmine Transdermal System highlights Mylan's continued investment in difficult-to-manufacture products - HERTFORDSHIRE, England and PITTSBURGH , July 9, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24
View HTML